PT  - JOURNAL ARTICLE
AU  - Alexander Lisitsa
AU  - Igor Klimanov
AU  - Svetlana Soodaeva
TI  - The effect of liposome inhalation on non-invasive oxidative stress markers in patients with bronchial asthma
DP  - 2011 Sep 01
TA  - European Respiratory Journal
PG  - p3961
VI  - 38
IP  - Suppl 55
4099  - http://erj.ersjournals.com/content/38/Suppl_55/p3961.short
4100  - http://erj.ersjournals.com/content/38/Suppl_55/p3961.full
SO  - Eur Respir J2011 Sep 01; 38
AB  - Background: The liposome inhalation demonstrates an antioxidant activity in the treatment of various diseases, confirmed both by experimental and clinical studies.The aim is to carry out a prospective study of antioxidant features of liposome admission in patients with the exacerbation of bronchial asthma.Materials and methods: We enrolled 50 patients (age=37±7.5 year, men=64%) with mild-to-moderate bronchial asthma (FEV1>70%, steroid-naive) in prospective comparison study. All patients were divided in two groups: group 1 contains 25 patients, who received a liposome inhalation by compression nebulizer once a day (300 mg of phospholipids in each admission); group 2 contains 25 patients, who received a traditional therapy (control). Antioxidant activity was determined by the estimation of the exhaled nitric oxide level (ENO) and total nitrite/nitrate (TNN) in exhaled breath condensate before and after the investigation period.Results: There was a significant decrease of ENO level in group 1 from 31.8±2.4 to 7.1±1.4 ppb (p<0.001) after the observing period. In group 2 the ENO level was decreased from 29.7±3.9 ppb to 25.0±2.5 ppb (not significant). Patients in both groups had significantly higher levels of TNN before the study (7.9±0.9 μ M and 8.4±1.1μM respetively). After liposome admission the TNN level in group 1 decreased to 0.9±0.1 μ M (p<0.01) as well as in control group it was at the same border (7.7±1.4 μM).Conclusion: The results obtained demonstrate that liposome inhalation administered once a day during 14-days period has a significant antioxidant effect in patients with mild-to-moderate bronchial asthma.